sibutramine has been researched along with Stroke in 5 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality." | 9.16 | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012) |
| "We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events." | 9.14 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010) |
| "The risk of AMI, stroke and either AMI or stroke was not higher among sibutramine users than comparable non-users of sibutramine in both Germany and the UK [Germany: HR 0." | 7.78 | Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study. ( Ferrufino, CP; Klingman, D; Lee, WC; Oleske, DM; Tyczynski, JE, 2012) |
| "This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized to lifestyle intervention with or without sibutramine for up to 6 years." | 5.17 | Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. ( Andersson, C; Caterson, I; Coutinho, W; Finer, N; Ghotbi, AA; James, WP; Køber, L; Sharma, AM; Torp-Pedersen, C; Van Gaal, LF, 2013) |
| "The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality." | 5.16 | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Legler, UF; Maggioni, AP; Perdok, RJ; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2012) |
| "We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events." | 5.14 | Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. ( Caterson, ID; Coutinho, W; Finer, N; James, WP; Maggioni, AP; Renz, CL; Rode, RA; Sharma, AM; Shepherd, GM; Torp-Pedersen, C; Van Gaal, LF, 2010) |
| "The marketing authorization for the weight loss drug sibutramine was suspended in 2010 following a major trial that showed increased rates of non-fatal myocardial infarction and cerebrovascular events in patients with pre-existing cardiovascular disease." | 3.81 | The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. ( Batterham, R; Bhaskaran, K; Douglas, I; Hayes, JF; Smeeth, L, 2015) |
| "The risk of AMI, stroke and either AMI or stroke was not higher among sibutramine users than comparable non-users of sibutramine in both Germany and the UK [Germany: HR 0." | 3.78 | Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study. ( Ferrufino, CP; Klingman, D; Lee, WC; Oleske, DM; Tyczynski, JE, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghotbi, AA | 1 |
| Køber, L | 1 |
| Finer, N | 3 |
| James, WP | 3 |
| Sharma, AM | 3 |
| Caterson, I | 1 |
| Coutinho, W | 3 |
| Van Gaal, LF | 3 |
| Torp-Pedersen, C | 3 |
| Andersson, C | 1 |
| Hayes, JF | 1 |
| Bhaskaran, K | 1 |
| Batterham, R | 1 |
| Smeeth, L | 1 |
| Douglas, I | 1 |
| Caterson, ID | 2 |
| Maggioni, AP | 2 |
| Shepherd, GM | 2 |
| Rode, RA | 2 |
| Renz, CL | 2 |
| Legler, UF | 1 |
| Perdok, RJ | 1 |
| Tyczynski, JE | 1 |
| Oleske, DM | 1 |
| Klingman, D | 1 |
| Ferrufino, CP | 1 |
| Lee, WC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event[NCT00234832] | Phase 3 | 10,777 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For each subject who died, the time to death was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 418 |
| Randomized Placebo | 404 |
For each subject, the first occurrence of a nonfatal MI included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 200 |
| Randomized Placebo | 159 |
For each subject, the time to first occurrence of a nonfatal stroke included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 127 |
| Randomized Placebo | 95 |
This outcome includes nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, CV death (including events such as fatal MI and fatal stroke), and any of the following revascularization procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft, coronary artery stent placement, cardiac transplant, peripheral vascular bypass or angioplasty, and carotid endarterectomy. For each subject, the POE or revascularization status (yes/no) and time to first occurrence of an event using time-to-event analysis were evaluated. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 927 |
| Randomized Placebo | 856 |
For each subject, the time to first occurrence of a resuscitated cardiac arrest included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 11 |
| Randomized Placebo | 7 |
For each subject, the time to cardiovascular death included in the POE was evaluated using time-to-event analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Randomized Sibutramine | 223 |
| Randomized Placebo | 229 |
For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis. (NCT00234832)
Timeframe: From randomization up to 6 years
| Intervention | Participants (Number) |
|---|---|
| Intent-to-treat population | |
| CV + DM Randomized to Placebo | 346 |
| CV + DM Randomized to Sibutramine | 403 |
| CV Only Randomized to Placebo | 66 |
| CV Only Randomized to Sibutramine | 77 |
| DM Only Randomized to Placebo | 77 |
| DM Only Randomized to Sibutramine | 79 |
| Randomized Placebo | 490 |
| Randomized Sibutramine | 561 |
3 trials available for sibutramine and Stroke
| Article | Year |
|---|---|
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Topics: Aged; Cardiovascular Diseases; Clinical Protocols; Cyclobutanes; Diabetes Mellitus, Type 2; Female; | 2013 |
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
Topics: Aged; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus | 2010 |
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind | 2012 |
2 other studies available for sibutramine and Stroke
| Article | Year |
|---|---|
The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom.
Topics: Anti-Obesity Agents; Appetite Depressants; Cohort Studies; Contraindications; Cyclobutanes; Female; | 2015 |
Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Obesity Agents; Child; Child, Preschool; Cohort Stu | 2012 |